Skip to main content

Advertisement

Table 1 Clinical and biochemical characteristics of patients with FCHL and control subjects

From: Vitamin D concentrations in familial combined hyperlipidemia: effects of lipid lowering treatment

  Cases (n = 59) Controls (n = 48) P
Age (years) 50.2 ± 11.6 46.5 ± 17.2 0.210
Sex (% men) 57.6 62.5 0.609
BMI (Kg/m2) 27.9 ± 4.1 25.4 ± 4.1 0.005
Waist (cm)    0.026
- Men 97.7 ± 9 91.79 ± 12.1
- Women 92.7 ± 12.4 88.8 ± 11.8
Glucose (mmol/L) 5.3 ± 0.6 4.9 ± 0.73 0.020
HbA1c (%) 5.6 ± 0.5 5.4 ± 0.6 0.135
Total cholesterol (mmol/L) 6.7 ± 1.6 4.8 ± 0.8 0.000
Triglycerides (mmol/L) 2.3 (1.1-15.8) 0.7 (0.3-2.1) 0.000
LDL-c (mmol/L) 4.1 ± 1.3 2.8 ± 0.7 0.000
HDL-c (mmol/L) 1.2 ± 0.4 1.6 ± 0.4 0.000
VLDL-c (mmol/L) 1.0 (0.5-7.6) 0.4 (0.1-1.2) 0.000
NEFA (mmol/L) 0.7 (0.2-4.3) 0.4 (0.1-1.1) 0.000
ApoB (g/L) 1.3 ± 0.3 0.8 ± 0.2 0.000
CRP (mg/L) 1.6 (0.2-21.5) 1.0 (0.2-15.0) 0.133
25(OH)D (nmol/L) 58.9 ± 24.5 69.1 ± 30.0 0.057
  1. P values according to T-test and Mann–Whitney test.
  2. FCHL: Familial combined hyperlipidemia, BMI: body mass index, HbA1c: glicated haemoglobin, LDL-c: low-density lipoprotein cholesterol, HDL-c: high-density lipoprotein cholesterol, VLDL-c: very low-density lipoprotein cholesterol, NEFA: non-esterified fatty acids, ApoB: apolipoprotein B, CRP: C-reactive protein, 25(OH)D: 25-hydroxyvitamin D.